In addition, during the Royalty Term (as defined below), while CymaBay supplies Licensed Product to Kaken, Kaken will make payments to CymaBay for each unit of Licensed Product that CymaBay supplies at a percentage of the Japanese National Health Insurance price of the Licensed Product that equates to 20+% royalties. If CymaBay is not supplying product to Kaken during the Royalty Term, a 20+% royalty payment will be payable to CymaBay by Kaken based on Kaken net sales of Licensed Product in Japan. After the Royalty Term, if CymaBay is supplying Licensed Product to Kaken, CymaBay will receive payments for each unit of Licensed Product based on a percentage of the Japanese National Health Insurance price of the Licensed Product that is lower than during the Royalty Term.